Cryoport Powers Cell Therapy Boom, Eyes Profitability Amid Record Growth

NASHVILLE, TN – March 03, 2026 – Cryoport, Inc. (NASDAQ: CYRX) today announced robust financial results for 2025, exceeding revenue guidance and signaling strong momentum carried by the explosive growth in the cell and gene therapy (CGT) market. The company, a critical player in the ultra-cold supply chain for life-saving medicines, reported full-year revenue of $176.2 million, a 12% increase from the previous year, and issued an optimistic forecast for continued growth in 2026.

The results paint a picture of a company solidifying its leadership in a highly specialized and rapidly expanding niche. As personalized medicines and regenerative therapies move from clinical trials to commercial reality, Cryoport's role as the logistical backbone for these temperature-sensitive treatments becomes increasingly vital.

The Engine Behind a Medical Revolution

Cryoport's performance is intrinsically linked to the breakthrough science of cell and gene therapy. These are not conventional pills but "living drugs"—therapies derived from a patient's own or a donor's cells—that require cryogenic temperatures, often as low as -196°C, to remain viable. A single temperature deviation can render a priceless, life-altering treatment useless.

This is where Cryoport has carved out its dominant market position. The company reported it now supports a record 760 global clinical trials, a key indicator of its deep integration into the biopharma development pipeline. Industry analyses suggest Cryoport handles the specialized logistics for a majority of all CGT trials, giving it unparalleled insight and a significant first-mover advantage as these trials progress.

"2025 was a year of strong progress for Cryoport," said CEO Jerrell Shelton in the company's announcement. He highlighted that revenue from supporting commercial CGTs surged 29% to $33.4 million, demonstrating the company's successful transition from supporting research to enabling commercial-scale distribution. With 20 commercially approved therapies already in its portfolio and a pipeline of 86 trials in the late-stage Phase 3, the foundation for future growth appears solid.

A Strategic Pivot Toward Profitability

While top-line growth is impressive, investors are closely watching Cryoport's path to profitability. The company's latest results show significant progress. Adjusted EBITDA from continuing operations, a key metric of operational efficiency, improved substantially, showing a loss of just $5.8 million for 2025 compared to a $17.8 million loss in 2024.

This improvement is the result of a deliberate strategic pivot. In June 2025, Cryoport completed the divestiture of its broader specialty courier business, CRYOPDP, to logistics giant DHL Group. The move not only provided a substantial capital infusion—contributing to a reported net income of $78.3 million for the year—but more importantly, it streamlined the company's focus on its core, high-margin life sciences services. The deal also established a strategic partnership with DHL, intended to enhance Cryoport's global reach, particularly in Europe and the Asia-Pacific region.

By shedding a more generalized logistics arm, Cryoport is doubling down on its expertise in the complex, high-value CGT space. The company's Life Sciences Services revenue grew 18% in 2025, with its BioStorage/BioServices segment jumping 22%, indicating that clients are increasingly relying on Cryoport for an integrated suite of services beyond simple shipping.

Investing in the Future of the Cold Chain

Armed with a strong balance sheet showing over $411 million in cash and short-term investments, Cryoport is aggressively investing to build a competitive moat. These investments are not just about expansion but about enhancing the resilience and capability of the entire CGT supply chain.

The company recently launched a state-of-the-art Global Supply Chain Center at the Charles de Gaulle airport in Paris, France, and has another major facility slated to open in Santa Ana, California, in late 2026. These hubs are strategically located to reduce transit times, navigate complex customs, and provide localized support for the increasing volume of commercial therapies.

Innovation extends to its product lines as well. MVE Biological Solutions, a Cryoport subsidiary, launched its new Fusion® 800 Series, a self-sustaining cryogenic freezer designed for space-constrained labs that eliminates the need for a constant liquid nitrogen supply. It also introduced integrated Condition Monitoring Solutions for its shipping containers, combining its trusted cryogenic systems with advanced, real-time tracking technology. This ensures a complete "chain of compliance," offering biopharma clients full visibility and audit-ready data for their invaluable shipments.

Navigating a Competitive and Expanding Market

Cryoport operates in a market with immense potential. The third-party logistics market for cell and gene therapies, valued at an estimated $1.81 billion in 2025, is projected to soar to nearly $17 billion by 2035. This growth has attracted formidable competitors, including specialized divisions of major logistics players like World Courier (Cencora) and Marken (UPS).

However, Cryoport's dedicated focus on an integrated, end-to-end cryogenic platform—from manufacturing its own cryogenic freezers to providing advanced logistics management software—remains a key differentiator. The company's strategy is to embed itself so deeply into the therapy lifecycle, from early research to commercial delivery, that it becomes an indispensable partner.

The company's guidance for 2026 projects revenue between $190 million and $194 million, representing 8-10% growth. While seemingly modest compared to past performance, it reflects a maturing base and a focus on sustainable expansion. The immediate future is promising, with the company anticipating 13 new therapy application filings and nine new therapy approvals for its clients in 2026. With three client therapies facing approval decisions in the coming two months, Cryoport's newly expanded infrastructure and refined strategy will quickly be put to the test.